motixafortide acetate · Ayrmid Pharma · NDA 217159
Aphexda
Earliest generic entry, as listed
29 Dec 2041
Blocked by patent: US 12257285, US 12268725.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12257285 | product | 29 Dec 2041 |
| US 12268725 | product | 29 Dec 2041 |
Exclusivities · 2 unexpired
| ODE-442 | orphan drug (7 years) | 8 Sep 2030 |
| NCE | new chemical entity (5 years) | 8 Sep 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217159 · 001 · RLD | powder, subcutaneous | EQ 62MG BASE/VIAL | 29 Dec 2041 |